Kurzfassung

A randomized, double blind, placebo controlled, mutli-centre, multi-national Phase II/III study to assesss the efficacy and safety of three different dose regimes of Oralgen Graspollen in patients with graspollen-relaeated allergic rhinoconjunctivititis